🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Austria / NCT07004400
Starting soon Not applicable

A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD

NCT07004400 · tracked via the Priya Life Science Austria tracker
Phase
Not applicable
Started
2025-08-01
Last updated
2025-06-04

Condition(s) studied

GERD (Gastroesophageal Reflux Disease)

Investigational drug(s) / intervention(s)

RefluxStop™ implantationNissen fundoplication

RefluxStop™ implantation: Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use

Nissen fundoplication: Standard surgical technique for Nissen fundoplication

Study summary

This study will evaluate if the RefluxStop™ device will treat your acid reflux and improve your symptoms and how it compares to the standard surgical treatment for GERD, the Nissen fundoplication.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Willing and able to provide informed consent and to participate in the clinical investigation; 2. Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older; 3. Documented GERD present for ≥ 12 months. Typical symptoms are defined as heartburn, which is a burning sensation often presented as a substernal pain; 4. 24-hour pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \< 4 for ≥ 4.5% of time during a 24-hour monitoring); 5. Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator Exclusion Criteria: 1. \> 8 cm sliding hernia and paraesophageal hernia; no mesh is allowed; 2. Manometry verified lack of or moderate or severe weak peristalsis in esophagus with DCI \<300 or pathologic LOS function including hypercontractability, spasm or pathologic nonrelaxing functionality (the latter defined as coordinated swallows in less than 70% of wet swallows or median IRP\>15mmHg). Hypercontractability defined as DCI \>8'000 or pressure \>45 mmHg. Thus, excluding from the study the rare diseases achalasia, scleroderma, and nutcracker esophagus, however, including mild esophageal motility disorder patients with mildly weak peristalsis; 3. History of bariatric or anti-reflux surgery; 4. Female subjects who are pregnant or nursing; 5. Known sensitivity or allergies to silicone materials; 6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the clinical investigation procedure (as outlined in the IFU); 7. Subjects that are unable to comply with the clinical investigation requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement);

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Universitätsklinik für Allgemeinchirurgie Klinische Abteilung für Viszeralchirurgie Vienna Austria
St. Elisabethen Krankenhaus Frankfurt Frankfurt Germany
Klinikum Friedrichshafen GmbH Friedrichshafen Germany
Klinik Beau-Site Hirslanden Bern Bern Switzerland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07004400 on ClinicalTrials.gov ↗ ← All trials in Austria